Overview

Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squmous Cell Carcinoma of Esophageus

Status:
Active, not recruiting

Trial end date:
2020-06-17

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and feasibility of preoperative immune checkpoint therapy with concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. And this study will provide valuable information for further clinical trials of preoperative pembrolizumab and other immune checkpoint therapy in esophageal cancer treatment.

Phase:

Phase 1

Details

Lead Sponsor:

Hecheng Li M.D., Ph.D

Treatments:

Pembrolizumab